×

Update in Lawsuit for Investors in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares announced by Shareholders Foundation

SAN DIEGO, June 21, 2016 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending in Massachusetts on behalf of certain purchasers of shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) over alleged Securities Laws Violations by Aegerion Pharmaceuticals.

Investors who purchased shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) prior to April 2013 and continue to hold any of those NASDAQ:AEGR shares have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

In November 2013, news reports revealed that Aegerion Pharmaceuticals, Inc. received an FDA Warning Letter in connection with statements the Company's CEO made regarding JUXTAPID capsules, during broadcast interviews on CNBC's television show, "Fast Money," that aired on June 5, 2013, and October 31, 2013.

On January 9, 2014, Aegerion Pharmaceuticals, Inc. reported its preliminary 2013 Net product sales, its outlook for 2014 and other business updates. Among other things, Aegerion Pharmaceuticals, Inc. announced that it has received a subpoena from the United States Department of Justice, represented by the U.S. Attorney’s Office in Boston, MA, requesting documents regarding the Company’s marketing and sale of JUXTAPID in the U.S.

On January 15, 2014 a lawsuit was filed against Aegerion Pharmaceuticals, Inc. over alleged securities laws violations. The plaintiff claimed that the defendants made allegedly false and/or misleading statements and/or failed to disclose to Aegerion Pharmaceuticals, Inc. investors that Aegerion Pharmaceuticals, Inc. marketed its drugs in violation of the FDCA, that as a result, Aegerion Pharmaceuticals, Inc. faced heightened regulatory scrutiny by the FDA and other governmental bodies, and that as a result of the foregoing, Aegerion Pharmaceuticals Inc.'s statements were allegedly materially false and misleading at all relevant times. In August 2015 an amended complaint was filed.

Those who purchased shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) prior to April 2013 and continue to hold any of those NASDAQ:AEGR shares have also certain options and should contact the Shareholders Foundation, Inc.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 mail@shareholdersfoundation.com 3111 Camino Del Rio North Suite 423 San Diego, CA 92108

Source:Shareholders Foundation, Inc.